Evidence map›Paper›PMID 36720568›Full record

ArticleBMJ open2023

Factors associated with COVID-19 vaccine uptake in people with kidney disease: an OpenSAFELY cohort study.

OpenSAFELY Collaborative, Edward Pk Parker, John Tazare, William J Hulme, Christopher Bates, Edward J Carr, Jonathan Cockburn, Helen J Curtis, Louis Fisher, Amelia Ca Green and 19 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 8 institutions in 1 country.

OpenSAFELY Collaborative
Edward Pk ParkerLondon School of Hygiene & Tropical Medicine, London, UK.
John TazareLondon School of Hygiene & Tropical Medicine, London, UK.
William J HulmeBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, Oxfordshire, UK.
Christopher BatesTPP, Leeds, UK.
Edward J CarrThe Francis Crick Institute, London, UK.
Jonathan CockburnTPP, Leeds, UK.
Helen J CurtisBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, Oxfordshire, UK.ORCID 0000-0003-3429-9576
Louis FisherBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, Oxfordshire, UK.
Amelia Ca GreenBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, Oxfordshire, UK.
Sam HarperTPP, Leeds, UK.
Frank HesterTPP, Leeds, UK.
Elsie Mf HornePopulation Health Sciences, University of Bristol, Bristol, UK.
Fiona LoudKidney Care UK, Alton, UK.
Susan LyonUK Kidney Association, Bristol, UK.
Viyaasan MahalingasivamLondon School of Hygiene & Tropical Medicine, London, UK.ORCID 0000-0002-3157-1127
Amir MehrkarBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, Oxfordshire, UK.
Linda NabBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, Oxfordshire, UK.
John ParryTPP, Leeds, UK.
Shalini SanthakumaranUK Renal Registry, Bristol, UK.
Retha SteenkampUK Renal Registry, Bristol, UK.
Jonathan Ac SternePopulation Health Sciences, University of Bristol, Bristol, UK.ORCID 0000-0001-8496-6053
Alex J WalkerBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, Oxfordshire, UK.ORCID 0000-0003-4932-6135
Elizabeth J WilliamsonLondon School of Hygiene & Tropical Medicine, London, UK.
Michelle WillicombeCentre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, UK.
Bang ZhengLondon School of Hygiene & Tropical Medicine, London, UK.
Ben GoldacreBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, Oxfordshire, UK.ORCID 0000-0002-5127-4728
Dorothea NitschLondon School of Hygiene & Tropical Medicine, London, UK.
Laurie A TomlinsonLondon School of Hygiene & Tropical Medicine, London, UK laurie.tomlinson@lshtm.ac.uk.ORCID 0000-0001-8848-9493
University of Oxford · GBRenal Association · GBLondon School of Hygiene & Tropical Medicine · GBUniversity of Bristol · GBImperial College Healthcare NHS Trust · GBThe Francis Crick Institute · GBKidney Care UK · GBWPP (United Kingdom) · GB

Funding

Medical Research Council MC_PC_20030Medical Research Council MC_PC_20051Medical Research Council MC_PC_20058Medical Research Council MC_PC_20059Medical Research Council MR/V015737/1Medical Research Council MR/V015757/1Medical Research Council MR/W016729/1Medical Research Council MR/W021420/1Wellcome Trust 222097/Z/20/Z
6 · The paper itself

Abstract

objectiveTo characterise factors associated with COVID-19 vaccine uptake among people with kidney disease in England.

designRetrospective cohort study using the OpenSAFELY-TPP platform, performed with the approval of NHS England.

settingIndividual-level routine clinical data from 24 million people across GPs in England using TPP software. Primary care data were linked directly with COVID-19 vaccine records up to 31 August 2022 and with renal replacement therapy (RRT) status via the UK Renal Registry (UKRR).

participantsA cohort of adults with stage 3-5 chronic kidney disease (CKD) or receiving RRT at the start of the COVID-19 vaccine roll-out was identified based on evidence of reduced estimated glomerular filtration rate (eGFR) or inclusion in the UKRR.

main outcome measuresDose-specific vaccine coverage over time was determined from 1 December 2020 to 31 August 2022. Individual-level factors associated with receipt of a 3-dose or 4-dose vaccine series were explored via Cox proportional hazards models.

results992 205 people with stage 3-5 CKD or receiving RRT were included. Cumulative vaccine coverage as of 31 August 2022 was 97.5%, 97.0% and 93.9% for doses 1, 2 and 3, respectively, and 81.9% for dose 4 among individuals with one or more indications for eligibility. Delayed 3-dose vaccine uptake was associated with younger age, minority ethnicity, social deprivation and severe mental illness-associations that were consistent across CKD severity subgroups, dialysis patients and kidney transplant recipients. Similar associations were observed for 4-dose uptake.

conclusionAlthough high primary vaccine and booster dose coverage has been achieved among people with kidney disease in England, key disparities in vaccine uptake remain across clinical and demographic groups and 4-dose coverage is suboptimal. Targeted interventions are needed to identify barriers to vaccine uptake among under-vaccinated subgroups identified in the present study.

Indexed as

COVID-19Kidney DiseasesKidney Failure, ChronicAdultCohort StudiesCOVID-19 VaccinesHumansRenal DialysisRetrospective StudiesCOVID-19 VaccinesCOVID-19Kidney & urinary tract disordersPublic health

Identifiers

PMID36720568
PMCPMC9890277
OpenAlexW4318712265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.